GID.AX: Summary for GIDYNAMICS CDI FORUS - Yahoo Finance

Australia Markets closed

GI Dynamics, Inc. (GID.AX)


ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.06+0.00 (+1.82%)
At close: 10:22AM AEDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close0.05
Open0.06
Bid0.04 x
Ask0.06 x
Day's range0.06 - 0.06
52-week range0.01 - 0.09
Volume175,000
Avg. volume823,484
Market cap30.97M
Beta3.13
PE ratio (TTM)-2.07
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire2 days ago

    GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe and the Middle East for patients with type 2 diabetes and obesity, announced that it will release its 2016 Annual Report on Form 10K on or before 31 March EDT | 1 April AEDT 2017. The webcast and presentation, which will provide a financial update on GI Dynamics, can be accessed at https://event.webcasts.com/starthere.jsp?ei=1141206 or on the GI Dynamics website, www.gidynamics.com, by clicking on the Investor Relations tab and going to the Events and Webcasts page. GI Dynamics, Inc. (ASX:GID.AX - News), is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity.

  • Business Wire12 days ago

    GI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Manoel Galvao Neto, M.D., and David E. Cummings, M.D., have joined the GI Dynamics SAB. The GI Dynamics SAB was created to further advance the body of evidence regarding EndoBarrier, ask and answer relevant questions about treatment using EndoBarrier, and advance the state of patient care with EndoBarrier.

  • Business Wire18 days ago

    GI Dynamics Announces New Scientific Advisory Board and Board’s First Two Members

    BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics®, Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB). The GI Dynamics SAB will endeavor to bring together distinguished physicians and scientists specializing in endocrinology, gastroenterology and metabolic surgery to advance the evidence-based understanding of EndoBarrier and support its optimal usage. Professor Carel Le Roux, MD, PhD and Professor Jan Willem Greve, MD, PhD, are the first two members to join the SAB.